• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

A reduction to practise for siRNA screening utilising high conent analysis (HCA) technologies

10 July 2012  •  Author(s): Anthony Mitchell Davies & Anne Marie Byrne, Department of Clinical Medicine Trinity College Dublin; Holger Erfle, BIOQUANT-Zentrum Ruprecht-Karls-Universität Heidelberg; Graham Donnelly, Rita Murray & Peadar MacGabhann, Biocroi Ltd

One of the major limitations of performing large-scale High Content Analysis (HCA) screens is reagent cost, indeed this fact has been a key driver in the development of assay size reduction strategies here at The Irish National Centre for High Content Screening and Analysis at Trinity College’s Department of Medicine.

As well as the obvious financial advantages of reducing assay volumes, we have also identified other key benefits to this approach, namely:

  • Higher throughput
  • Improved signal to noise
  • Suited for the use of valuable cells, e.g. primary cells
  • Reduced storage and research space
  • Improved mixing of reagents

The practicalities of performing cell based assays at the nano-litre scale

Despite the clear benefits to adopting miniaturisation, there are several significant barriers that must be overcome before these methods can be utilised. These are sample delivery / handling and environmental stability.

The rest of this content is restricted to logged-in subscribers. Login or register (it's free!) to view the full content.

Comments are closed.

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringFIND OUT MORE
+ +